News & Updates

Survodutide, a glucagon receptor–glucagon-like peptide-1 (GLP-1) receptor dual agonist, significantly reduces body weight and liver/visceral fat in individuals with obesity as well as those with obesity and at-risk metabolic dysfunction–associated steatotic liver disease (MASLD) in the phase III SYNCHRONIZE-1 and SYNCHRONIZE-MASLD trials. The data, presented at ADA 2026, also demonstrate improvements in cardiometabolic parameters indicating broad benefits associated with survodutide treatment. 

A Singapore study has observed a high prevalence of symptomatic venous thromboembolism (VTE) in patients who underwent distal femur fracture (DFF) surgery. Those with advanced age or who are overweight are more likely to develop symptomatic VTE.